Plasma ADMA concentrations associate with aerobic fitness in postmenopausal women

Achan, 2003, Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase, Arterioscler Thromb Vasc Biol, 23, 1455, 10.1161/01.ATV.0000081742.92006.59 Allain, 1974, Enzymatic determination of total serum cholesterol, Clin Chem, 20, 470, 10.1093/clinchem/20.4.470 Bełtowski, 2006, Asymmetric dimethylarginine (ADMA) as a target for pharmacotherapy, Pharmacol Rep, 58, 159 Böger, 1998, Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia, Circulation, 98, 1842, 10.1161/01.CIR.98.18.1842 Böger, 2009, Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community, Circulation, 119, 1592, 10.1161/CIRCULATIONAHA.108.838268 Cooke, 2004, Asymmetrical dimethylarginine: the Uber marker?, Circulation, 109, 1813, 10.1161/01.CIR.0000126823.07732.D5 Eid, 2004, Relationship between obesity, smoking, and the endogenous nitric oxide synthase inhibitor, asymmetric dimethylarginine, Metabolism, 53, 1574, 10.1016/j.metabol.2004.06.026 Fabian, 2012, Age-related modification of antioxidant enzyme activities in relation to cardiovascular risk factors, Eur J Clin Invest, 42, 42, 10.1111/j.1365-2362.2011.02554.x Finley, 1978, Cholesterol in high-density lipoprotein: use of Mg2+/dextran sulfate in its enzymic measurement, Clin Chem, 24, 931, 10.1093/clinchem/24.6.931 Fox, 1971, Physical activity and the prevention of coronary heart disease, Ann Clin Res, 3, 404 Furuki, 2008, Plasma level of asymmetric dimethylarginine (ADMA) as a predictor of carotid intima-media thickness progression: six-year prospective study using carotid ultrasonography, Hypertens Res, 31, 1185, 10.1291/hypres.31.1185 Hanssen, 2011, Exercise-induced alterations of retinal vessel diameters and cardiovascular risk reduction in obesity, Atherosclerosis, 216, 433, 10.1016/j.atherosclerosis.2011.02.009 Hasegawa, 2007, Role of asymmetric dimethylarginine in vascular injury in transgenic mice overexpressing dimethylarginie dimethylaminohydrolase 2, Circ Res, 101, e2, 10.1161/CIRCRESAHA.107.156901 Hawkins, 2003, Rate and mechanism of maximal oxygen consumption decline with aging: implications for exercise training, Sports Med, 33, 877, 10.2165/00007256-200333120-00002 Kielstein, 2003, Asymmetric dimethylarginine, blood pressure, and renal perfusion in elderly subjects, Circulation, 107, 1891, 10.1161/01.CIR.0000060496.23144.A7 Kohlmeier, 1986, Direct enzymic measurement of glycerides in serum and in lipoprotein fractions, Clin Chem, 32, 63, 10.1093/clinchem/32.1.63 Leiper, 1999, Biological significance of endogenous methylarginines that inhibit nitric oxide synthases, Cardiovasc Res, 43, 542, 10.1016/S0008-6363(99)00162-5 Leong, 2008, Asymmetric dimethylarginine independently predicts fatal and nonfatal myocardial infarction and stroke in women: 24-year follow-up of the population study of women in Gothenburg, Arterioscler Thromb Vasc Biol, 28, 961, 10.1161/ATVBAHA.107.156596 Malatesta, 2004, Aerobic determinants of the decline in preferred walking speed in healthy, active 65- and 80-year-olds, Pflugers Arch, 447, 915, 10.1007/s00424-003-1212-y McMurray, 1998, Is physical activity or aerobic power more influential on reducing cardiovascular disease risk factors?, Med Sci Sports Exerc, 30, 1521, 10.1097/00005768-199810000-00009 Miyazaki, 1999, Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis, Circulation, 99, 1141, 10.1161/01.CIR.99.9.1141 Pialoux, 2009, Effect of cardiorespiratory fitness on vascular regulation and oxidative stress in postmenopausal women, Hypertension, 54, 1014, 10.1161/HYPERTENSIONAHA.109.138917 Schulze, 2005, Determination of a reference value for N(G), N(G)-dimethyl-l-arginine in 500 subjects, Eur J Clin Invest, 35, 622, 10.1111/j.1365-2362.2005.01561.x Slein, 1963, d-Glucose: determination with hexokinase and glucose-6-phosphate dehydrogenase, 117 Sydow, 2003, ADMA and oxidative stress, Atheroscler Suppl, 4, 41, 10.1016/S1567-5688(03)00033-3 Sydow, 2005, Insulin resistance: potential role of the endogenous nitric oxide synthase inhibitor ADMA, Vasc Med, 10, S35, 10.1177/1358836X0501000106 Tanaka, 2000, Aging, habitual exercise, and dynamic arterial compliance, Circulation, 102, 1270, 10.1161/01.CIR.102.11.1270 Thompson, 2003, Circulation, 107, 3109, 10.1161/01.CIR.0000075572.40158.77 Usui, 1998, Increased endogenous nitric oxide synthase inhibitor in patients with congestive heart failure, Life Sci, 62, 2425, 10.1016/S0024-3205(98)00225-2 Valkonen, 2001, Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine, Lancet, 358, 2127, 10.1016/S0140-6736(01)07184-7 Vallance, 1992, Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure, Lancet, 339, 572, 10.1016/0140-6736(92)90865-Z Yamashita, 2008, Evaluation of a homogeneous assay for measuring LDL-cholesterol in hyperlipidemic serum specimens, J Atheroscler Thromb, 15, 82, 10.5551/jat.E527